Steroid Responsive Acute Inflammatory Demyelinating Polyneuropathy Induced by an Immune Check Point Inhibitor
DOI:
https://doi.org/10.17161/rrnmf.v3i4.18080Keywords:
Acute Inflammatory Demyelinating Polyneuropathy, nerve conduction study, intravenous immunoglobulin, steroids, immune check point inhibitorsMetrics
Downloads
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209-249.
Rihawi K, Gelsomino F, Sperandi F, et al. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. Ther Adv Respir Dis. 2017;11(9):353-373.
Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer. 2016;60:210-225.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO. 2018;36(17):1714-1768.
de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N Engl J Med. 2016;375(3):296-297.
de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. N Engl J Med. 2016;375(3):296-297.
Manam R, Martin JL, Gross JA, et al. Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy. Cureus. Published online September 27, 2018.
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review: CIPN. Ann Neurol. 2017;81(6):772-781.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Najwa Al-Bustani MD, Zulfiqar Hussain MD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
